文献类型：期刊文献

英文题名：Autologous bone marrow stem cell therapy for patients undergoing coronary artery bypass grafting: A meta-analysis of 14 randomized controlled trials

作者：Wu, Shanlian[1,2,3,4];Yao, Liang[3];Yan, Peijing[3];Bao, Qiangwei[1,2];Dong, Xin[5];Liu, Xingguang[6];Zhu, Yan[7];Su, Xin[7,8];Wang, Aqian[7,8];Duan, Yichao[7];Yang, Kehu[3,4];Zhang, Min[2];Cao, Yunshan[7]

第一作者：Wu, Shanlian

通信作者：Zhang, M[1];Cao, YS[2]

机构：[1]Gansu Univ Chinese Med, Dept Pathol, Sch Basic Med, Lanzhou 730000, Gansu, Peoples R China;[2]Gansu Prov Hosp, Dept Pathol, 204 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China;[3]Gansu Prov Hosp, Inst Clin Res & Evidence Based Med, Lanzhou 730000, Gansu, Peoples R China;[4]Lanzhou Univ, Dept Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou 730000, Gansu, Peoples R China;[5]Third Hosp Gansu Prov, Dept Ultrasound, Lanzhou 730020, Gansu, Peoples R China;[6]Gansu Prov Hosp, Dept Cardiac Surg, Lanzhou 730000, Gansu, Peoples R China;[7]Gansu Prov Hosp, Dept Cardiol, 204 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China;[8]Gansu Univ Chinese Med, Dept Cardiol, Sch Clin Med, Lanzhou 730000, Gansu, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Pathol, 204 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China;[2]corresponding author), Gansu Prov Hosp, Dept Cardiol, 204 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China.

年份：2019

卷号：17

期号：4

起止页码：2985

外文期刊名：EXPERIMENTAL AND THERAPEUTIC MEDICINE

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000463793600076)】；

基金：This study was supported by the National Natural Science Foundation of China (grant no. 81770300), the International Cooperation Exchange Project of Gansu province (grant no. 18YF1WA046), the Science and Technology Projects of Lanzhou, China (grant no. 2016-2-57) and CAS 'Light of West China' Program granted to MZ.

语种：英文

外文关键词：bone marrow; stem cell; coronary artery bypass; meta-analysis; randomized controlled trial

摘要：Autologous bone marrow stem cell (BMSC) therapy is a novel option for regenerative therapy in patients with ischemic heart disease. The aim of the present meta-analysis was to evaluate the effectiveness of BMSCs combined with coronary artery bypass grafting (CABG). The PubMed, Cochrane Library, EMBASE and Web of Science databases were searched from inception to November 22, 2017 for randomized controlled trials on BMSC therapy combined with CABG. Finally, 14 trials with a total of 596 participants were included. Data were analyzed using a random-effects model. Compared with the control group, the BMSC therapy group exhibited an improvement in the left ventricular (LV) ejection fraction from baseline to follow-up [mean difference (MD)=4.36%; 95% confidence interval (CI): 1.90-6.81%; P<0.01]. Analysis of the pooled results revealed non-significant differences in the LV end-diastolic volume (MD=-6.27 ml; 95% CI: -22.34 to 9.80 ml; P=0.44), LV end-diastolic volume index (MD=-15.11 ml/m(2); 95% CI: -31.53 to 1.30 ml/m(2); P=0.07), LV end-systolic volume (MD=-11.52 ml; 95% CI: -26.97 to 3.93 ml; P=0.14) and LV end-systolic volume index (MD=-16.56 ml/m(2); 95% CI: -37.75 to 4.63 ml/m(2); P=0.13) between the BMSC and CABG alone groups. Therefore, autologous BMSC therapy for patients undergoing CABG appears to be associated with an improvement in LV function compared with CABG alone.